Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Janssen-Cilag International N.V
Woman and Man
Between 18 years
and 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
CR100956 : Essai de phase 2, évaluant l’efficacité et la tolérance d’une thérapie ciblée, l’ibrutinib (PCI-32765), inhibiteur de la tyrosine kinase de Bruton, chez des patients ayant un lymphome folliculaire réfractaire. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance de l’ibrutinib, chez des patients ayant un lymphome folliculaire réfractaire ou en rechute après deux lignes de traitement. Les pati...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
CR100845 : Essai de phase 1, évaluant la dose optimale, la tolérance, la pharmacocinétique et l’efficacité du JNJ-42756493, chez des patients ayant une tumeur solide ou un lymphome avancé ou réfractaire. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de déterminer la dose optimale à administrer, la tolérance, la pharmacocinétique et l’efficacité du JNJ-42756493, chez des patients ayant une tumeur solide ou un lymphome a...
Country
France
organs
Lymphomes non hodgkinien
,
Tumeurs solides
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
- To evaluate the efficacy of guselkumab in subjects with active PsA by assessing the reduction in signs and symptoms of PsA. - To assess the safety and tolerability of guselkumab in subjects with ac...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
Study to Evaluate Efficacy and Safety of Treatment with CNTO 136 in Subjects with Active Lupus Nephritis
The primary objective is to evaluate the efficacy and safety of CNTO 136 administered intravenously (IV) in subjects with active, International Society of Nephrology (ISN)/Renal Pathology Society (R...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
A Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin and Sitagliptin Therapy
In subjects with T2DM who have inadequate glycemic control on maximally or near-maximally effective doses of metformin and on sitagliptin, after 26 weeks of treatment: •To assess the effect of canagl...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007
The primary objective is to demonstrate the safety and tolerability of fulranumab subcutaneous (SC) injections compared with SC placebo, in subjects with standard of care and who have signs and sympto...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
The study will evaluate daratumumab separately in three relapsed or refractory NHL subtypes that are CD38 positive: MCL, DLBCL, and FL. There are two main objectives: -To assess overall response rat...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis
The purpose of this study is to assess the efficacy and safety of ustekinumab in adult participants with active nonradiographic axial spondyloarthritis (nr-AxSpA) measured by the reduction in signs an...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
Étude CR100844 : Étude de phase 1b, évaluant la tolérance et la dose maximale tolérée de l’ibrutinib en association avec une chimiothérapie standard R-CHOP comprenant du rituximab, du cyclophosphamide, de la doxorubicine, de la vincristine et de la prednisone, chez des patients ayant un lymphome non-hodgkinien (LNH) à cellules B CD20-positif. [essai clos aux inclusions]
L’objectif de cette étude est d’établir la dose recommandée d’ibrutinib à administré en association avec une chimiothérapie standard R-CHOP (rituximab, cyclophosphamide, doxorubicine, vincristine et p...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia
The primary objectives of this study are to evaluate the efficacy and safety of 3 fixed doses of paliperidone palmitate administered i.m. after an initial loading dose of 150 mg eq. for a total of 13 ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next